Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/9/2020
SIETES contiene 93097 citas

 
 
<< anterior 21 a 40 de 75 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TME, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen T, d'Emden MC, Crimet DC, O'Connell RL, Colman PG, for the FIELD Study Investigators. Effect of fenofibrate on the need for lase treatment for diabetic reniopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97. [Ref.ID 81560]
22.Tiene citas relacionadas Cita con resumen
Simó R, Hernández C. Fenofibrate for diabetic retinopathy. Lancet 2007;370:1667-8. [Ref.ID 81552]
24.
Nissen SE, Nicholls SJ, Wolski K, Howey DC, McErlean E, Wang MD, Gomez EV, Russo JM. Effects of a potent and selective PPAR-alfa agonist in patients with atherogenic dyslipidemia or hypercholesterolemia. Two randomized controlled trials. JAMA 2007;297:1362-73. [Ref.ID 79772]
26. Cita con resumen
Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006;333:1267-9. [Ref.ID 78882]
27.Tiene citas relacionadas Cita con resumen
Keech A, Simes J, Barter P, Best J, Scott R, Taskinen MR, on behalf of the FIELD Management Committee. Correction to the FIELD study report. Lancet 2006;368:1415. [Ref.ID 78331]
28. Cita con resumen
Anónimo. AstraZeneca and Abbott link up for combined lipid therapy. Scrip 2006;3173:7. [Ref.ID 77436]
29.Tiene citas relacionadas Cita con resumen
Sheth HG, Aslam S, DAvies N. Lipid lowering drugs in diabetes. Lipid lowering has ophthalmic benefits. BMJ 2006;332:1272-3. [Ref.ID 77101]
30.Tiene citas relacionadas Cita con resumen
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, for the FIELD Study Investigators. The FIELD study. Lancet 2006;367:1142-3. [Ref.ID 76583]
31.Tiene citas relacionadas Cita con resumen
Sirtori CR. The FIELD study. Lancet 2006;367:1141-2. [Ref.ID 76582]
32.Tiene citas relacionadas Cita con resumen
Föger B. The FIELD study. Lancet 2006;367:1141. [Ref.ID 76581]
34.Tiene citas relacionadas Cita con resumen
35.
Ireland JHE, Eggert CH, Arendt CJ, Williams AW. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ann Intern Med 2005;142:949-50. [Ref.ID 74176]
36.
Bergman AJ, Murphy G, Burke J, Zhao JJ, Valesky R, Liu L, Lasseter KC, He W, Prueksaritanont T, Qiu Y, Hartford A, Vega JM, Paolini JF. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004;44:1054-62. [Ref.ID 71291]
37.
Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 2004;3:101-11. [Ref.ID 69641]
38. Cita con resumen
Mayer Jr O, Simon J, Holubec L, Pikner R, Subrt I. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. Eur J Clin Pharmacol 2003;59:367-71. [Ref.ID 67581]
39.
Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS. Comparative effects of atorvastatin, simavastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 2003;43:825-30. [Ref.ID 67095]
40.
Dierkes J, Westphal S, Luley C. Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management. Drug Saf 2003;26:81-91. [Ref.ID 64865]
Seleccionar todas
 
<< anterior 21 a 40 de 75 siguiente >>